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Emerging evidence suggests that cellular metabolism plays a critical role in regulating immune activation. Alterations in energy and
lipid and amino acid metabolism have been shown to contribute to type I interferon (IFN) responses in macrophages, but the
relationship between metabolic reprogramming and the establishment of early antiviral function remains poorly deﬁned. Here,
we used transcriptional proﬁling datasets to develop global metabolic signatures associated with early IFN-α responses in two
primary macrophage model systems: mouse bone marrow-derived macrophages (BMM) and human monocyte-derived
macrophages (MDM). Short-term stimulation with IFN-α (<4 hours) was associated with signiﬁcant metabolic rewiring, with
>500 metabolic genes altered in mouse and human macrophage models. Pathway and network analysis identiﬁed alterations in
genes associated with cellular bioenergetics, cellular oxidant status, cAMP/AMP and cGMP/GMP ratios, branched chain amino
acid catabolism, cell membrane composition, fatty acid synthesis, and β-oxidation as key features of early IFN-α responses.
These changes may have important implications for initial establishment of antiviral function in these cells.
1. Introduction
Type I interferons (IFN) (IFN-α and IFN-β) play a seminal
role in antiviral, antibacterial, and antitumour responses
and act as critical regulators of the innate and adaptive
immune system [1–5]. These pleiotropic cytokines are pro-
duced following engagement of pattern recognition receptors
and signal through the ubiquitously expressed transmem-
brane IFN-α receptor (IFNAR), composed of IFNAR1 and
IFNAR2 subunits [5–7]. Cellular responses to type I IFN
are cell type- and context-dependent and vary during the
course of an immune response [8–11]. The variability in
these responses are due, in part, to the cumulative eﬀects of
JAK-STAT, the p38 MAP kinase (MAPK), the MAP kinase
kinase/ERK/MAPK signal-interacting kinase, and the phos-
phatidylinositol 3-kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) signaling pathways [11–13].
Emerging evidence suggests that cellular metabolism
plays a critical role in regulating and ﬁne tuning immune
function [14–16]. Alterations in cellular bioenergetics, amino
acid metabolism, and lipid metabolism have been shown to
aﬀect cytokine production, signaling protein activity, and cell
diﬀerentiation [17–19]. In macrophages, stimulation with
type I IFNs has been shown to increase glycolytic ﬂux,
inhibit sterol biosynthesis, shift lipid metabolism from de
novo synthesis to lipid import, and increase tryptophan
catabolism [20–25]. This metabolic reprogramming is
required to mount functional antiviral responses and has
been shown to regulate antigen presentation, inﬂammatory
mediator production, phagocytosis eﬃciency, and intracel-
lular killing [26, 27].
Recent studies suggest metabolic adaptations in macro-
phages occur at the molecular level (i.e., gene expression)
very early during the process activation and functional
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polarization [28–30]. In lipopolysaccharide- (LPS-) stimu-
lated macrophages, cellular activation has been shown to
undergo stages of time-resolved metabolic reprogramming
into initiation, early, and ampliﬁcation phases [28]. To date,
there has been no systematic characterization of metabolic
reprogramming associated with type I IFN responses,
particularly when examined as a function of time. In the
current study, we used transcriptional proﬁling to evaluate
global changes in metabolic gene expression following short-
term IFN-α stimulation (<4hours) in two well-characterized
primary macrophage model systems: mouse bone marrow-
derived macrophages (BMM) and human monocyte-derived
macrophages (MDM). Our ﬁndings provide a systematic
understanding of altered metabolic genes associated with
early IFN-α responses in BMM and MDM and identify
potential metabolic mechanisms that may contribute to
initial establishment of antiviral immune responses.
2. Materials and Methods
2.1. Microarray Normalization and Processing. Microarray
datasets were extracted from the Gene Expression Omnibus
(GEO) repository from the National Center for Biotechnol-
ogy Information (NCBI). Datasets were identiﬁed using the
search terms “Macrophage Interferon” and “Type I
Interferon” [31]. A total of 10 datasets were identiﬁed using
these search criteria. Two studies were identiﬁed that
assessed short-term stimulation (<4 hours) in either mouse
bone marrow-derived macrophages (BMM) or human
monocyte-derived macrophages (MDM). The selected
BMM dataset [32] diﬀerentiated bone marrow cells in
DMEM media with 10 ng/mL of macrophage colony-
stimulating factor (M-CSF), 10% FBS, and 1% penicillin/
streptomycin for seven days before replacing the media on
day six. BMM were stimulated with 62U/mL IFN-α
(approximately 1 ng/mL) for 2.5 hours prior to cell lysis and
RNA extraction (Supplementary Figure S1). The selected
MDM dataset [33] isolated monocytes via adherence
(4 hours) and diﬀerentiated cells in DMEM media with
2mM L-glutamine, 100U/mL penicillin, 100μg/mL
streptomycin, and 10% FCS for 7 days. After diﬀerentiation,
MDM were treated with 10ng/mL IFN-α for 4 hours prior to
cell lysis and RNA extraction (Supplementary Figure S1).
Raw gene expression data was normalized by median
centering, and preprocessing was performed in dChip
[34]. Probes were excluded from the analysis when present
calls (p < 0 05) were identiﬁed in less than 20% of samples.
2.2. Identiﬁcation of Signiﬁcant Metabolic Genes in IFN-
Stimulated Macrophages. Metabolic genes were identiﬁed
using the MetScape plugin in Cytoscape [35–37]. These
genes were identiﬁed by mapping Entrez Gene IDs to meta-
bolic pathways found in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) and Edinburgh Human Metabolic
Network (EHMN) databases. Manual curation was per-
formed to identify metabolic genes that did not map to
KEGG or EHMN pathways. Fold change (FC) analyses,
p values, and false discovery rates (FDR) were calculated
in R. Diﬀerentially expressed genes were deﬁned as a
−1.2≤FC≥1.2, p value ≤ 0 05, and FDR ≤ 0 1. This fold
change cutoﬀ was selected to be inclusive of small diﬀerences
in gene expression. Biologically relevant alterations in meta-
bolic gene expression were identiﬁed by combining FC with
pathway and network analyses. Classiﬁcation analyses
including principal component analysis (PCA), partial least
squares-discriminant analysis (PLS-DA), random forest
(RF), and unsupervised hierarchical clustering were per-
formed in MetaboAnalyst [38]. Gene Set Enrichment Analy-
sis (GSEA) [39] was performed using the hallmark gene sets
(H; n = 50), the curated gene sets (C2; n = 4731), and the GO
gene sets (C5; n = 5917) fromMolecular Signatures Database
(MSigDB) version 6.0. Signiﬁcant enrichment was deﬁned as
a p ≤ 0 05 and FDR < 0 25. Metabolic pathway enrichment
and topology analysis were performed in MetaboAnalyst.
Signiﬁcant enrichment of metabolic datasets was deﬁned as
p ≤ 0 05. Metabolic network annotation and analysis were
performed in Cytoscape and the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [40, 41].
The work ﬂow is shown in Figure 1(a).
3. Results
3.1. Type I IFN Stimulation of Mouse BMM and Human
MDM Is Associated with Enrichment of Metabolic Gene
Sets. Of the >45,000 unique probe sets analyzed across the
two datasets, 28,903 and 29,479 probes were identiﬁed as
present in the BMM andMDMdatasets, respectively. In total,
7338 genes were diﬀerentially expressed in IFN-α-stimulated
BMM compared to unstimulated controls (Supplementary
Table S1). Conversely, 3804 genes were diﬀerentially
expressed in IFN-α stimulated MDM compared to controls
(Supplementary Table S2). GSEA identiﬁed signiﬁcantly
enriched gene sets within each dataset. Two hundred and
eighty-ﬁve gene sets were enriched in BMMdistributed across
three main functional categories including immune signaling
and function (n = 151), cellular metabolism (n = 40), and
other biological states and processes (n = 94). Enriched
metabolic processes in BMM included glycolysis and
gluconeogenesis, the regulation of nitric oxide biosynthetic
process, and tryptophan, arginine, and proline metabolism
(Supplementary Table S3). In MDM, GSEA identiﬁed 948
enriched gene sets (immune signaling and function: n = 360,
cellular metabolism: n = 107, and other biological states
and processes: n = 481). Enriched metabolic processes
included reactive oxygen species (ROS) metabolism and
biosynthesis, tryptophan metabolism, regulation of steroid
biosynthetic process, and regulation of oxidoreductase
activity (Supplementary Table S4).
3.2. Metabolic Genes Represent Important Classiﬁers of Early
Type I IFN Responses in BMM and MDM. Given the signif-
icant enrichment of metabolic gene sets in GSEA analysis,
we used MetScape to identify all metabolic genes detected
across datasets. Of the >1600 metabolic genes identiﬁed,
517 and 354 were altered following short-term IFN-α
stimulation of BMM and MDM, respectively (−1 2 ≤ FC
≥ 1 2, p value ≤ 0 05, FDR ≤ 0 1). Ninety-four genes were
altered in both datasets with the same directionality (either
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upregulated or downregulated) (Figure 1(b)) including
genes associated with cellular bioenergetics (PFKFB3,
PDP), tryptophan metabolism (KMO, WARS), nucleotide
metabolism (NT5C3, CNP), and lipid metabolism
(SPTLC2, AGPAT5, SQLE, and SOAT1). PCA showed a
clear separation between the control and IFN-α-treated
samples in both BMM and MDM based on the metabolic
gene subset (Figure 1(c)). Similarly, random forest analysis
classiﬁed control and IFN-α-stimulated cells with 100%
predictive accuracy using metabolic genes. Variable impor-
tance in projection (VIP) analysis identiﬁed genes involved
in nucleotide degradation (PNP, AMPD3) and lipid metab-
olism (ETNK1, HMGCS1) as top classiﬁers in IFN-α stim-
ulation in BMM. Top classiﬁers in MDM included genes
associated with glycolysis (PFKFB3), tryptophan catabo-
lism (KYNU), and reactive oxygen species production
(GCH1, SOD2) (Figures 2(c) and 2(d)). Only EIF2AK2,
NAMPT, and NT5C3 and the ubiquitin-related gene
USP18 overlapped as top classiﬁers across datasets. EIF2AK2
is involved in mRNA translation and inﬂammasome
activation [42], NAMPT is a key NAD+producing gene
[43], and NT5C3 is an antiviral pyrimidine nucleotidase [44].
Pathway enrichment and topology analysis identiﬁed
enrichment in purine, pyrimidine, inositol phosphate, and
branched-chain amino acid metabolism in addition to lysine
degradation in both BMM and MDM. Metabolic pathways
uniquely enriched in BMM included arginine and proline
metabolism, steroid biosynthesis, sphingolipid and glycero-
phospholipid metabolism (Figure 2(a), Supplementary
Figure S2). Metabolic pathways uniquely enriched in MDM
included amino sugar and nucleotide sugar metabolism,
nicotinate and nicotinamide metabolism, galactose
metabolism, and fatty acid (FA) metabolism (Figure 2(b),
Supplementary Figure S2).
3.3. Short Term IFN-α Stimulation Alters Genes Associated
with Energy Metabolism in BMM and MDM. To better func-
tionally characterize diﬀerential gene expression in IFN-α-
stimulated BMM and MDM, altered genes (−1 2 ≤ FC ≥ 1 2,
p value ≤ 0 05, FDR ≤ 0 1) were mapped to metabolic
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Figure 1: Short term IFN-α stimulation is associated with altered expression of metabolic genes in human monocyte-derived macrophages
(MDM) and mouse bone marrow-derived macrophages (BMM). (a) Workﬂow used to identify diﬀerentially expressed metabolic genes in
IFN-α-stimulated mouse BMM (2.5 hours) and human MDM (4 hours). Metabolic genes were identiﬁed in MetScape using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) and the Edinburgh Human Metabolic Network (EHMN) databases. (b) Venn diagram
showing the number of metabolic genes common to the BMM (yellow) and MDM (blue) datasets (FC > 1 2, p < 0 05, FDR < 0 10). (c)
Principal component analysis (PCA) of metabolic gene sets from BMM (left) and MDM (right) following IFN-α stimulation (n = 517 and
354 metabolic genes in the BMM and MDM datasets, resp.).
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pathways and networks. Consistent with the literature [20],
short-term IFN-α stimulation of BMM was associated with
an upregulation of glycolytic genes (HK2,HK3, PGM2, PFKP,
PFKFB3, and INSR) compared to unstimulated controls
(Figure 3, Supplementary Figure S3). Key genes involved in
pyruvate metabolism were also altered in BMM following
IFN-α stimulation. Whereas pyruvate dehydrogenase kinase
3 (PDK3) was upregulated, pyruvate dehydrogenase
phosphatase 1 (PDP1) and dihydrolipoamide dehydrogenase
(DLD) were downregulated. These alterations may aﬀect the
activity of the pyruvate dehydrogenase complex (PDH) and
increase lactate production. Consistent with these ﬁndings,
lactate dehydrogenase D (LDHD) was also upregulated in
IFN-α-stimulated BMM. Interestingly, IFN-α-stimulated
BMMs also upregulated levels of isocitrate dehydrogenase
(IDH3A) and the downregulation of DLD and
dihydrolipoamide S-succinyltransferase (DLST) expression.
DLD and DLST are key components of the oxoglutarate
dehydrogenase complex (OGDC) and play an important role
in converting 2-oxoglutarate to succinyl-CoA. Along the
succinate-fumarate-malate axis, succinate dehydrogenase
complex subunit A (SDHA) was downregulated in
stimulated compared to unstimulated BMM. SDHA is the
major catalytic subunit of the succinate-ubiquinone
oxidoreductase. Altered SDHA expression may also have
signiﬁcant eﬀects on oxidative phosphorylation (OXPHOS).
Short-term IFN-α stimulation of MDM was not associ-
ated with signiﬁcant alterations in glycolytic genes or genes
linked to lactate production (Figure 3, Supplementary
Figure S3). Alternatively, stimulation was associated with
the downregulation of genes associated with the conversion
of galactose to glucose (GALK2, GALT, and GALE) and
glycogen breakdown (INSR, PHKA1, PHKA2, PHKG2, and
AGL). Early responses in MDM were associated with
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Figure 2: Metabolic genes are top classiﬁers of IFN-α stimulation in BMM and MDM. (a) Pathway enrichment and topology analysis of
mouse BMM and human MDM following IFN-α stimulation (p < 0 05). Analyses were performed using all metabolic genes. The blue bars
represent enrichment analysis. The yellow bars represent topology scores. (b) Top metabolic classiﬁers of IFN-α stimulation were
identiﬁed using variable importance in projection (VIP) scores based on PLS-DA models (p < 0 05). Analyses were performed using all
metabolic genes (p < 0 05). Red and green in the heat map represent upregulation and downregulation of gene expression, respectively.
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increased levels of phosphofructokinase (PFK) activator
PFKFB3, which assists in the production of pyruvate from
glucose and pyruvate dehydrogenase complex component X
(PDHX), which may facilitate acetyl-CoA production from
pyruvate. IFN-α was also associated with the upregulation
of genes associated with OXPHOS including genes from
complexes I and V of the electron transport chain (NDUFA9,
NDUFS4, and ATP5G3) and the glycerol phosphate shuttle
(glycerol 3-phosphate dehydrogenase 2 [GPD2]). Collec-
tively, these results suggest that early changes in energy
metabolism may play an important role in the initiation of
antiviral responses in both BMM and MDM.
3.4. IFN-α-Stimulated BMM and MDM Show Signs of
Alterations in Genes Associated with Redox Regulation. Given
the link between energy metabolism and ROS metabolism
[45–47], we next examined alterations between early IFN-α
responses and genes linked to cellular redox status (oxidant
and antioxidant genes). In BMM, IFN-α short-term stimula-
tion was associated with altered expression of genes associ-
ated with the nitric oxide cycle including the upregulation
of argininosuccinate synthetase 1 (ASS1) and nitric oxide syn-
thase 1 (NOS1), and downregulation of arginase 2 (ARG2)
expression, which may favour ﬂux of arginine towards NO
production (Figure 4, Supplementary Figure S4). Early IFN-
α responses in BMM were also associated with the downreg-
ulation of genes associated with the antioxidant response
(superoxide dismutase 2 (SOD2), glutamate-cysteine ligase,
catalytic subunit (GCLC), NAD kinase (NADK), and thiore-
doxin reductase 1 and 3 (TXNRD1, TXNRD3)) and the upreg-
ulation of thioredoxin interacting protein (TXNIP), which
inhibits the antioxidant activity of thioredoxin [48, 49].
Alternatively, IFN-α stimulation of MDM was associated
with the upregulation of antioxidant genes including SOD2
and myeloperoxidase (MPO) as well as genes associated with
glutathione production (glutamate-cysteine ligase, modiﬁer
subunit (GCLM) and NAD+ kinase (NADK)) (Figure 4,
Supplementary Figure S4). Short-term IFN-α was also
associated with upregulation of and glutaredoxin (GLRX),
thioredoxin 1 (TXN1), and thioredoxin-interacting protein
(TXNIP). These alterationsmay help regulate electron linkage
and subsequent ROS production associated with the
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Figure 3: Genes associated with bioenergetic processes are diﬀerentially expressed in mouse BMM and human MDM following IFN-α
stimulation. Signiﬁcantly altered (−1 2 ≤ FC ≥ 1 2, p value ≤ 0 05, FDR ≤ 0 1) metabolic genes involved in energy production were mapped
to their respective pathways using MetScape and DAVID. Green and red represent genes that have been signiﬁcantly upregulated or
downregulated, respectively. Blue represents genes that were not altered following IFN-α stimulation.
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upregulation of genes associated with OXPHOS in these cells
(Figures 3 and 4).
3.5. Early Type I IFN Responses Are Associated with
Alterations in Genes Associated with cAMP and cGMP
Production. Given the enrichment of gene sets associated
with nucleotide metabolism in both datasets, we examined
the speciﬁc eﬀects on short-term IFN-α stimulation on
purine and pyrimidine metabolism. In BMM, short-term
stimulation was associated with the downregulation of ami-
dophosphoribosyltransferase (PPAT) and UMP synthetase
(UMPS). These enzymes play a central role in ribose 5-
phosphate incorporation during de novo purine and pyrimi-
dine synthesis, which may represent an antiviral mechanism.
At the level of purine degradation, IFN-α was associated
with an upregulation of purine nucleoside phosphorylase
(PNP), guanine deaminase (GDA), xanthine dehydrogenase
(XDH), and ectonucleoside triphosphate diphosphohydro-
lase 2 and 5 (ENTPD2, ENTPD5) suggesting increased deg-
radation. Interestingly, IFN responses were also associated
with alterations in genes that regulate cyclic guanine mono-
phosphate (cGMP)/GMP and cyclic adenosine monopho-
sphate (cAMP)/AMP ratios (Figure 5, Supplementary
Figure S5). Four phosphodiesterases (PDE4D, PDE7A,
PDE7B, and PDE8B) and two adenylate cyclases (ADCY2,
ADCY4) were upregulated, and adenylate kinase (ADK)
and AMP deaminase 3 (AMPD3) were downregulated in
stimulated versus unstimulated cells. These proﬁles suggest
that IFN-α-activated BMM may accumulate both AMP and
cAMP. IFN-α stimulation of BMM was also associated with
the upregulation of guanylate kinase (GUK) and downregula-
tion of phosphodiesterase 1B (PDE1B), suggesting these cells
may favour cGMP production.
In MDM, IFN-α stimulation was not associated with
signiﬁcant changes in genes associated with de novo
purine synthesis. However, IFN-α was associated with the
downregulation of carbamoyl phosphate synthetase 2,
aspartate transcarbamylase, and dihydroorotase (CAD), a
protein responsible for the ﬁrst three enzymatic steps of the
pyrimidine biosynthesis pathway. Genes involved in nucleo-
side production within the purine and pyrimidine degrada-
tion pathways, such as GMP reductase (GMPR), AMPD3,
5′-nucleotidase, cytosolic II (NT5C2), and adenosine deami-
nase (ADA), are found to be upregulated in MDM which
suggests an increase in nucleotide salvaging (Figure 5,
Supplementary Figure S5). At the level of cGMP/GMP and
cAMP/AMP regulation, the downregulation of PDE6D and
adenylate cyclase 7 (ADCY7) as well as the upregulation of
PDE4B and two soluble forms of guanylate cyclase
(GUCY1A3, GUCY1B3) suggest a shift towards cGMP and
AMP production. Varied expression of these bioactive nucle-
otides that function as intracellular secondary messengers
may contribute to early type I IFN responses.
3.6. Short-Term IFN-α Stimulation Is Associated with
Alterations in Tryptophan and Branched-Chain Amino Acid
Catabolism in BMM and MDM. Consistent with the litera-
ture [50, 51], alterations in genes associated with tryptophan
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Figure 4: IFN-α stimulation of MDM is associated with increased expression of genes associated with ROS production and antioxidant
responses. Diﬀerentially expressed metabolic genes (−1 2 ≤ FC ≥ 1 2, p value ≤ 0 05, FDR ≤ 0 1) were mapped to pathways associated with
cellular redox status using MetScape and DAVID. Green and red represent genes that have been signiﬁcantly upregulated or
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and branched-chain amino acid catabolism were pro-
nounced in early IFN-α responses. Both BMMs and MDMs
exhibited a pronounced upregulation of genes associated
with tryptophan catabolism via the kynurenine pathway
(Figure 6, Supplementary Figure S6). While IFN-α-stimu-
lated BMM upregulated tryptophan 2,3-dioxygenase
(TDO2) and KMO, stimulation of MDM was associated with
the upregulation of KMO and kynureninase (KYNU). This
shift in tryptophan catabolism was accompanied by the
upregulation of nicotinamide phosphoribosyltransferase
(NAMPT), suggesting an increased ﬂux of tryptophan
towards NAD+ production.
Both IFN-α-activated BMM and MDM showed altered
expression of genes associated with branched-chain amino
acid (Figure 6, Supplementary Figure S6). In BMMs, IFN-α
stimulation leads to the upregulation of genes associated with
isoleucine (propionyl-CoA carboxylase; PPCA, 3-ketoacyl-
CoA thiolase 1A and 2; ACAA1A/2) and valine (3-
hydroxyisobutyrate dehydrogenase; HIBADH) catabolism.
Upregulation of AU RNA binding/methylglutaconyl-CoA
hydratase (AUH) and downregulation of methylcrotonoyl-
CoA carboxylase 1 (MCCC1) and 3-hydroxymethyl-3-
methylglutaryl-CoA lyase (HMGCL) suggest decreased
leucine catabolism in BMM. However, AUH may be
functioning in its secondary role in promoting mRNA
degradation [52]. InMDM, IFN-α stimulation was associated
with a downregulation of multiple genes associated with
branched-chain amino acid catabolism including branched-
chain aminotransferase 2 (BCAT2), isovaleryl-CoA
dehydrogenase (IVD), hydroxyacyl-CoA dehydrogenase
(HADH), and methylmalonyl-CoA epimerase (MCEE).
Together, this indicates that alterations in branched-chain
amino acid catabolism may be key to driver of early IFN-α
responses in primarymacrophage systems.
3.7. IFN-α Stimulation Is Associated with Altered Lipid
Metabolism in BMM and MDM. Lipid metabolism has been
shown to play an important role in antiviral responses in
BMM and MDM [53]. Several studies have reported alter-
ations in cholesterol metabolism during IFN and antiviral
responses [21–23]. Here, we also identiﬁed alterations in
genes associated with phospholipid and sphingolipid metab-
olism and FA biosynthesis following short-term IFN
responses. Consistent with previous studies, short-term
IFN-α stimulation of BMM and MDM was associated with
the downregulation of genes associated with de novo choles-
terol synthesis (Figure 7, Supplementary Figure S7). In BMM,
IFN-α was associated with the downregulation of genes
involved in mevalonate synthesis (HMGCS1, HMGCR),
lanosterol synthesis (FDFT1, SQLE, and LSS) and cholesterol
synthesis (CYP51,MSMO1,HSD17B7, and SC5D). It was also
associated with the downregulation of genes associated with
cholesterol ester formation and the upregulation of carboxyl
ester lipase (CEL), cholesterol 25-hydroxylase (CH25H), and
sterol 27-hydroxylase (CYP27A1). In MDM, IFN-α stimula-
tion was associated with decreased levels of SQLE and sterol
O-acyltransferase 1 (SOAT1) and increased levels of CH25H.
SQLE catalyzes the ﬁrst oxygenation step in sterol biosyn-
thesis and is thought to be a rate-limiting enzyme of this
process [54].
At the level of phospholipid and sphingolipid metabo-
lism, IFN-α-treated BMM upregulated phospholipid phos-
phatase 2 (PLPP2) and neutral ceramidase (ASAH2) and
downregulated sphingolipid kinases (SPHK2, CERK) sug-
gesting a shift away from phosphorylated sphingolipids
to sphingosine in acute IFN responses (Figure 7, Supple-
mentary Figure S7). Stimulation of BMM was also associ-
ated with the upregulation of 1-acylglycerol-3-phosphate
O-acyltransferase 1 (AGPAT1) and phosphatidate
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cytidylyltransferase 1 (CDS1), which may increase cytidine
diphosphate- (CDP-) diacylglycerol production, a precursor
for phosphatidylinositol, phosphatidylglycerol, and cardioli-
pin synthesis. Phosphatidylinositol is a minor component
on the cytosolic side of cell membranes, and cardiolipin is
an important component of the inner mitochondrial mem-
brane [55]. Consistent with these ﬁndings, IFN-α stimulation
was associated with the upregulation of three diﬀerent phos-
pholipase A2 (PLA2G2D, PLA2G4A, and PLA2G16) genes
and the downregulation of two phospholipase D (PLD1,
PLD2) genes. These genes cleave phosphatidylcholine and
phosphatidylethanolamine, which represent the major phos-
pholipids in mammalian membranes. The relative ratio of
these lipids to one another within the cell membrane has sig-
niﬁcant implications on membrane integrity [55]. In MDM,
PLA2G4A and sphingomyelin synthase 1 (SGMS1) were
upregulated and lysophospholipid acyltransferase (LPCAT4)
and PLA2G15 were downregulated following IFN-α stimula-
tion (Figure 7, Supplementary Figure S7). IFN-α stimulation
was also associated with the downregulation of AGPAT5,
choline kinase alpha (CHKA), and ethanolamine kinase 1
(ETNK1), which play an important role in the synthesis of
phosphatidylglycerol, phosphatidylcholine, and phosphati-
dylethanolamine. Collectively, these alterations suggest
IFN-α responses may alter the composition of the plasma
and mitochondrial membranes of BMM and MDM as part
of early type I IFN responses.
Finally, at the level of fatty acid synthesis, IFN-α stimula-
tion of BMM was also associated with the downregulation of
FA synthase (FAS) and FA desaturase 1 (FADS1) as well as
the upregulation of carnitine palmitoyltransferase 1A
(CPT1A). Alternatively, in MDM, IFN-α was associated with
the upregulation of long-chain fatty acid- (LCFA-) produc-
ing aldehyde dehydrogenase 3b1 (ALDH3B1) and three
acyl-CoA synthetase long-chain genes (ACSL1, ACSL5, and
ACSL6) and the downregulation of carbonyl reductase 4
(CBR4), acetyl-CoA carboxylase-α (ACACA), mitochondrial
3-oxoacyl-ACP synthase (OXSM), trimethyllysine hydrolase
ε (TMLHE), and hydroxyacyl-CoA dehydrogenase
(HADH). Diﬀerences in fatty acid metabolism may indicate
diﬀerential dependencies of BMM and MDM on β-
oxidation for energy production.
4. Discussion
In the current study, we used publicly available transcrip-
tional proﬁling datasets to develop metabolic gene signatures
associated with short-term IFN-α stimulation in mouse and
human macrophage models. Enrichment analysis, pathway
mapping, and network construction identiﬁed alterations in
central metabolic pathways in early IFN-α responses includ-
ing glycolysis, oxidative phosphorylation, redox regulation,
nucleotide metabolism, amino acid catabolism, and lipid
metabolism. BMM had increased expression of genes associ-
ated with aerobic glycolysis, nitric oxide production,
branched-chain amino acid metabolism, and fatty acid β-
oxidation as well as decreased expression of genes associated
with cholesterol biosynthesis. MDM had increased expres-
sion of genes associated with increased OXPHOS activity
and antioxidant production and decreased expression of
genes associated with branched-chain amino acid catabolism
and fatty acid β-oxidation. While the current study only
examines alterations in gene expression, these ﬁndings sug-
gest that metabolic rewiring, at the level of transcription, is
a key feature of early IFN-α responses. Future studies are
required to validate the identiﬁed gene signatures and to val-
idate the biological relevance of these alterations during early
antiviral immune responses.
A number of studies have reported increased aerobic
glycolysis and reduced oxidative phosphorylation in
macrophages following activation with inﬂammatory
stimuli [56–59]. Consistent with the literature, short-term
IFN-α stimulation of BMM was associated with increased
expression of genes associated with glycolysis (HK2, HK3,
PGM2, PFKP, PFKFB3, and INSR) and lactate production
(LDHD) and decreased expression of genes associated with
pyruvate production (PDK3, PDP1, and DLD) and ﬂux
through the TCA cycle (DLD, DLST, and SDHA). In
addition to meeting bioenergetic requirements of the cells,
these alterations may increase intracellular levels of
bioactive metabolites such as D-lactate, α-ketoglutarate, and
succinate. Lactate accumulation in the microenvironment
has been shown to suppress cytokine production and
migration of human cytotoxic T cells [60, 61]. Similarly, α-
ketoglutarate has been shown to quell inﬂammatory
processes by suppressing NF-κB-mediated inﬂammatory
pathways [62]. Succinate can also modulate inﬂammatory
cytokine production. A recent study found that succinate
stabilizes HIF-1α expression in LPS-activated macrophages
[14], which facilitates HIF-1α transport into the nucleus
where it induces the expression of glycolytic targets such as
LDHA, HK2, and PKM2, as well as inﬂammatory genes
such as IL1B [63, 64]. Inhibition or decreased expression
of succinate dehydrogenase (SDH) has been shown to
promote IL-10 expression and to repurpose the
mitochondria for ROS production [19]. While functional
studies are required to validate these proﬁles, our
ﬁndings suggest bioenergetic reprogramming of BMM
may represent a feedforward mechanism that may
contribute to the immunomodulatory properties of type I
IFNs during early antiviral immune responses.
Unlike BMM, short-term IFN-α stimulation of MDM
was associated with the upregulation of a range of genes asso-
ciated with the electron transport chain, which may favour
OXPHOS for energy production. While OXPHOS provides
more ATP per glucose molecule compared to aerobic glycol-
ysis, energy and metabolic precursor production occurs more
slowly. Further, IFN-α stimulation of MDM was associated
with the downregulation of genes associated with the Leloir
pathway (GALK2, GALT, and GALE), which is responsible
for the conversion of galactose to glucose. Recent studies
have shown that T cells, but not B cells, can be activated
and proliferate in the presence of galactose when glucose is
absent [65, 66]. However, unlike activation in glucose-rich
environments, T cells in galactose are forced to rely on
OXPHOS for energy production, which occurs at signiﬁ-
cantly slower rates [65]. This reliance on galactose also results
in suboptimal IFN-γ and IL-2 production suggesting
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galactose should only be used when no other energy substrate
is available [65]. Thus, decreased expression of genes associ-
ated with the Leloir pathway inMDMmay represent a means
by which cells can improve the eﬃciency of energy produc-
tion while maintaining functional immune responses.
Transcriptional proﬁling also identiﬁed redox regulation
as a key feature of early IFN-α responses in mouse and
human primary macrophage models. In BMM, IFN-α repro-
gramming was associated with increased expression of genes
associated with nitric oxide (NO) production (ASS1, NOS1,
and NAGS) and decreased antioxidants (SOD2, GCLC,
TXNRD1, and TXNRD3). NO is a potent antimicrobial mol-
ecule that has been shown to modulate cellular metabolism
[67–70] and immune function [71]. ASS1 and ASL are part
of the aspartate-argininosuccinate shunt, which recycles cit-
rulline to resynthesize arginine for prolonged NO production
[72, 73]. In M1 macrophages, increased expression of ASS1
and the subsequent increased ﬂux through this shunt has
been shown to replenish TCA cycle intermediates following
decreased IDH and SDH gene expression [72]. Unlike
BMM, IFN-α-stimulated MDM had increased expression of
genes associated with OXPHOS and ROS production. ROS
are also potent antimicrobial molecules, capable of killing
intracellular pathogens [74]. The matched upregulation of
antioxidant genes (e.g., glutathione, glutaredoxin, and thior-
edoxin) in conjunction with ROS likely reﬂects a protective
mechanism to limit any associated cellular damage. Inter-
estingly, a recent study found that the reducing nature of
glutathione can prime T cell inﬂammatory responses by
promoting mTOR-activated metabolic reprogramming
[75]. It is currently unclear if similar priming occurs in
macrophages. Collectively, our data suggest mouse BMM
and human MDM may adopt diﬀerential metabolic strate-
gies to mount intracellular antimicrobial responses during
acute IFN responses.
Pathway mapping and network reconstruction identiﬁed
IFN-α-associated alterations in nucleotide metabolism. In
both BMM and MDM, IFN-α stimulation was associated
with a downregulation of genes associated with de novo
pyrimidine biosynthesis. A number of viruses including
human cytomegalovirus and herpes simplex viruses require
de novo pyrimidine synthesis for propagation and survival
[76, 77]. Furthermore, inhibitors of de novo pyrimidine bio-
synthesis have broad antiviral eﬀects against RNA, DNA, and
retroviruses such as inﬂuenza A, hepatitis C, human adenovi-
rus, and human immunodeﬁciency virus (HIV) [78, 79]. In
MDM, IFN-α stimulation was also associated with increased
expression of genes associated with purine and pyrimidine
degradation pathways and nucleotide salvaging. The induc-
tion of nucleotide degradation pathways may act as a coun-
terstrategy against viral-driven nucleotide biosynthesis [80].
Moreover, the activation of nucleotide salvaging pathways
may allow the cell to recycle degraded bases and nucleosides
and produce nucleotides to maintain cellular function.
Interestingly, IFN-α responses were also associated with
alterations in genes that regulate cGMP/GMP and cAMP/
AMP ratios. Cyclic nucleotide second messengers, including
cAMP and cGMP, are potent secondary messengers that
contribute to the regulation of a variety of cellular processes
including metabolism [81]. cAMP has been shown to
suppress innate immune function including inﬂammatory
cytokine production, cell adhesion, phagocytosis, and intra-
cellular killing [82, 83]. Additionally, the cAMP axis plays
an important role in antimicrobial defense as many microbes
have evolved virulence-enhancing strategies that exploit this
pathway [84–86]. In BMM, LPS responses are associated
with low levels of cAMP and cGMP accumulation, which
inhibit inﬂammatory cytokine production [87, 88]. Thus,
alterations in the cAMP/AMP and cGMP/GMP ratio
may play an important role in regulating inﬂammatory,
antimicrobial, and metabolism responses in acute type I
IFN responses.
Alterations in genes associated with tryptophan and
branched-chain amino acid catabolism were pronounced
in early IFN responses. Consistent with previous studies
[50, 89, 90], IFN-α stimulation was associated with
increased levels of genes associated with tryptophan catab-
olism. While we did not observe alterations in IDO1
expression, TDO2, KMO, and KYNU were increased in
both BMM and MDM. Many studies have shown that
tryptophan catabolism (via IDO activation) represents a
potent antiviral immune response [90–92]. Our study sug-
gests downstream enzymes of the kynurenine pathway
may also contribute to this phenotype. Interestingly, we
also found that NAMPT was upregulated following acute
IFN-α stimulation, suggesting tryptophan may be directed
towards NAD+ salvaging. NAMPT plays an important role
in regulating glycolytic ﬂux, phagocytic activity, and TNF-
α production in LPS-stimulated macrophages and may
also contribute to IFN responses [93, 94]. At the level of
branched-chain amino acid metabolism, BMM had
increased expression of genes associated with branched-
chain amino acid catabolism. Conversely, MDM downreg-
ulated genes associated with this pathway. Catabolic
products of branched-chain amino acid metabolism feed
into the TCA cycle contributing to the production of
succinyl-CoA and acetyl-CoA [95]. Previous studies have
shown that branched-chain amino acid availability is crit-
ical for lymphocyte proliferation and M1 macrophage acti-
vation, but little is known regarding the role of these
amino acids in regulating immune responses [96, 97].
Thus, upregulation of branched-chain amino acid catabo-
lism in BMM may compensate for the loss of OXPHOS
activity, which is not required in MDM.
Lipid metabolism has been shown to play an important
role in antiviral responses in BMM and MDM [23, 24, 53].
Consistent with the literature, altered gene expression in
BMM and MDM suggest these cells may downregulate de
novo cholesterol synthesis and shunt available free choles-
terol towards the production of oxysterols including 25-
hydroxycholesterol and 27-hydroxycholesterol. The role of
cholesterol ﬂux in antiviral responses has been described pre-
viously [21–23]. Increased cholesterol levels help facilitate
the entry of the dengue virus during the early phases of infec-
tion, which is reduced by the presence of oxysterols such as
25-hydroxycholesterol [22, 98–100]. Macrophages can also
counteract this demand by switching away from de novo syn-
thesis towards lipid import [23]. Limiting ﬂux through the
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cholesterol biosynthetic pathway induces a STING-mediated
type I IFN response, which can be attenuated by exogenous
free cholesterol [21, 23]. We also observed signiﬁcant alter-
ations in genes associated with phospholipid, sphingolipid,
and FA metabolism. Lipid membrane composition can play
a critical role in the antiviral capabilities of immune cells.
Sphingolipids and phosphatidylserine have been shown to
function as receptors for polyomavirus, HIV, and vesicular
stomatitis virus (VSV) [101–103]. Altering the lipid compo-
sition of the plasma membrane is a vital protective strategy
against viral entry by altering the potential interaction sites
for viruses [104, 105]. Thus, altering the membrane lipid
composition may be a critical feature of metabolic repro-
gramming in early antiviral responses.
Collectively, our study provides critical new insights into
the molecular underpinnings of metabolic reprogramming
associated with short-term IFN-α responses in mouse
BMM and human MDM. This is the ﬁrst study to systemat-
ically characterize changes in metabolic gene expression
using transcriptional proﬁling in this context. However, we
acknowledge certain limitations of this study. The current
study only evaluates gene expression proﬁles via microarray.
Validation and functional testing is required to understand
the biological relevance of these ﬁndings. While both BMM
and MDM were stimulated with short-term IFN-α, we can-
not exclude the possibility that some of the reported diﬀer-
ences may reﬂect the length of time in stimulant (2.5 h
versus 4 h). Preliminary studies from our laboratory suggest
metabolic proﬁles in stimulated BMM are similar within a
2–6-hour window. However, future time-course studies are
required to examine how metabolic signatures change in
BMM and MDM over short- and long-term IFN-α stimula-
tion. Culture conditions and diﬀerentiation protocols may
also aﬀect metabolic proﬁles in BMM versus MDM. This lim-
itation should be an important consideration across all stud-
ies examining relationships between immune and metabolic
processes in vitro, whether in humans or in mice. Careful
consideration of the model system may be required depend-
ing on downstream applications of the ﬁndings. Meta-
analyses of transcriptional datasets may represent a powerful
tool to identify metabolic signatures that are consistently
altered across diﬀerent studies using diﬀerent models, time
points, culture conditions, and so on. To minimize these
eﬀects, only studies performed in high glucose DMEM (plus
glutamine and sodium pyruvate) with 10% FBS were selected
for analyses. Finally, both BMM and MDM were analyzed
using Aﬀymetrix technologies’ microarray chips. However,
we cannot exclude the possibility that the reported diﬀer-
ences may be aﬀected by the microarray used. Despite these
limitations, we strongly believe this comparative study
provides important new insights into metabolic processes
that contribute to IFN responses inmouse and humanmacro-
phages. We believe that the power of an untargeted approach
such as transcriptional proﬁling is to systematically character-
ize these diﬀerences, which may have important implications
on eﬀector function depending on the local microenviron-
ment. In the future, more targeted studies are required to eval-
uate the eﬀects of these gene expression proﬁles on protein
expression and functional metabolic and immune responses.
5. Conclusions
In summary, this study identiﬁed a variety of metabolic path-
ways altered following short-term IFN-α stimulation inmouse
and human macrophage systems. This may have important
implications for the initiation of early antiviral immune
responses, including the induction of the speciﬁc antimicro-
bial and immunomodulatory functions of IFN-α. While func-
tional studies are required to clearly elucidate the relationships
between this metabolic reprogramming and eﬀector func-
tion, it is clear that transcriptional regulation of metabolic
processes is a key feature of early type I IFN responses. An
in-depth understanding of this early reprogramming may
lead to the development of targeted therapeutics that regulate
and ﬁne tune speciﬁc type I IFN eﬀector function.
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Supplementary Materials
Supplementary Table S1. A list of all metabolic genes iden-
tiﬁed in the BMM dataset.
Supplementary Table S2. A list of all metabolic genes iden-
tiﬁed in the MDM dataset.
Supplementary Table S3. A list of signiﬁcantly altered gene
sets identiﬁed by GSEA in the BMM dataset.
Supplementary Table S4. A list of signiﬁcantly altered gene
sets identiﬁed by GSEA in the MDM dataset.
Supplementary Figure S1. Workﬂow of BMM and MDM dif-
ferentiation and IFN-α stimulation. Mouse bone marrow
cells and human monocytes were diﬀerentiated for 7 days
into BMM and MDM, respectively. Cells were then stimu-
lated with IFN-α for less than 4 hours. RNA was extracted
from total cells and prepared for microarray analysis.
Supplementary Figure S2. IFN-α is associated with diﬀeren-
tial enrichment of metabolic pathways in mouse BMM com-
pared to human MDM. Metabolite set enrichment analysis
(MSEA) was performed in MetaboAnalyst using metabolic
gene datasets. Pathways shown were signiﬁcantly enriched
(P < 0 05) in either IFN-stimulated BMM, MDM, or both.
Yellow and blue represent enrichment scores in BMM and
MDM, respectively (error bars = sem; n = 3).
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Supplementary Figure S3. IFN-α responses are associated
with altered bioenergetic proﬁles in mouse and human mac-
rophages. The bar plots show signiﬁcantly altered genes asso-
ciated with bioenergetics pathways (FC> 1.2, p < 0 05,
FDR< 0.10). Light blue and dark blue represent expression
levels in unstimulated (control) and IFN-α-treated macro-
phages, respectively (error bars = sem; n = 3).
Supplementary Figure S4. BMM and MDM express redox-
related genes following short-term IFN-α stimulation. The
bar plots show signiﬁcantly altered genes associated with cel-
lular redox pathways (FC> 1.2, p < 0 05, FDR< 0.10). Light
blue and dark blue represent expression levels in unstimu-
lated (control) and IFN-α-treated macrophages, respectively
(error bars = sem; n = 3).
Supplementary Figure S5. IFN-α is associated with altered
expression of genes that regulate nucleotide metabolism
and cAMP/cGMP ratios. The bar plots show signiﬁcantly
altered genes associated with nucleotide metabolism
(FC> 1.2, p < 0 05, FDR< 0.10). Light blue and dark blue
represent expression levels in unstimulated (control) and
IFN-α-treated macrophages, respectively (error bars = sem;
n = 3).
Supplementary Figure S6. Short-term IFN-α stimulation is
associated with alterations in tryptophan and branched chain
amino acid catabolism. The bar plots show signiﬁcantly
altered genes associated with tryptophan and branched chain
amino acid metabolism (FC> 1.2, p < 0 05, FDR< 0.10).
Light blue and dark blue represent expression levels in unsti-
mulated (control) and IFN-α-treated macrophages, respec-
tively (error bars = sem; n = 3).
Supplementary Figure S7. Altered expression of genes associ-
ated with lipid metabolism is a key feature of IFN-α
responses. The bar plots show signiﬁcantly altered genes
associated with lipid metabolism (FC> 1.2, p < 0 05,
FDR< 0.10). Light blue and dark blue represent expression
levels in unstimulated (control) and IFN-α-treated macro-
phages, respectively (error bars = sem; n = 3).
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